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Platelet-activating factor (P AF) is a potent inflamma-
tory Inediator that has been shown to be produced by 
human keratinocytes and is thought to playa role in 
cutaneous inflammation. Immunofluorescence and 
radioligand binding studies were used to characterize 
P AF receptors (P AF-R) on human keratinocytes and 
the human epidermoid cell lines A-431 and HaCaT. 
Indirect immunofluorescence studies demonstrated 
anti-P AF-R staining of primary cultures of human 
keratinocytes, A-431 cells, and HaCaT cells. Primary 
cultures of human fibroblasts and the melanoma cell 
line SK-30 failed to show immunostaining above that 
seen with control antiserum. With indirect immuno-
fluorescence studies of sections of normal human 
skin, a granular anti-P AF-R staining pattern was 
noted on the keratinocyte cell membranes. A-431 
cells readily metabolized P AF by deacetylation-
reacylation at 37°C, but not at 4°C. Binding studies 
on crude membrane preparations of A-431 cells con-
ducted at 4°C demonstrated specific binding that 
P latelct-activating facto r (1-alkyl-2-acetyl-glycero-3-phosphocholine; PA F) is a potent activator of many cell types including plate lets, vascular endothelium , n eutro-phi ls, mast cells, and monocytes [1, 2]. By acting as both a chemoattractant to recruit and as a stimulus to activate 
granulocytic cells, PAF h as profound proinflammatory effccts . In 
addition to the proinflammatory effects found with the stimu lation 
of the above cell types, PAF h as mitogenic efFccts on cultured 
smooth muscle and lymphoblastic cell lin es [3-5] , The majority of 
PAl" actions are thought to be exerted through inte raction with a 
specifi c receptor, because radioligand binding studies usin g 
[3H]PAF have demonstrated high-affinity binding sites o n PAF-
responsive cells, and various structurally dissimilar PAF receptor 
antagonists can inhibit PAl" effects [6]. The PAF receptor (PAF-R) 
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reached saturation by 120 min. Scatchard analysis of 
PAF binding data revealed a single class of high-
affinity (Ko = 6.3 ± 0.3 nM) PAF binding sites. The 
immunofluorescence and radioligand binding sites 
were shown to be functional PAF-Rs, as 10 pM to 1 
#-tM P AF increased intracellular calciuln in primary 
cultures of human keratinocytes, A-431 cells, and 
HaCaT cells, whereas PAF treatment of primary cul-
tures of human fibroblasts or the m,elanoma cell line 
SK-30 did not result in changes in the intracellular 
calcium concentration. The structurally dissimilar 
PAF-R antagonists CV-6209, Ro19-3704, and alpra-
zolam all inhibited the PAF-induced calcium changes 
in A-431 cells. The CV -6209 inhibition was seen at doses 
that competed with the P AF binding to these cells. 
These studies provide the first evidence for the pres-
ence of a functional P AF-R expressed on human kera-
tinocytes, suggesting d"lat tIns lipid mediator may play 
an important role in normal keratinocytes or in inflam-
matory dennatology.] [,,,,est DemratoI105:816-823, 1995 
has been cloned fi'om guinea pig lung [7] and hum an leukocytes [8]. 
The elucidated structure of the PAF-R places it in the G-protein-
coupled rhodopsin class receptor r.,mi ly. with seven putative trans-
membrane domains . 
The PAF-R is functionally lin ked to phosphoinosito l hydrolysis, 
and activatio n resu lts in the production of inosito l-l ,4,5-trisphos-
phate and diacylglycerol [9]. lnositol-l ,4,5-trisphosp hate mobilizes 
intracellular calcium, and diacylg lycero l activates prote in kinase C . 
PAF also affects cyclic nucl eotides by inhibi ting cyclic adenosine 
m onophosphate accumulation [1 0]. PA F activates microtubule-
associated protein-2-kinase [11] and induces express ion of the earl y 
response gene c:los [12). 
Several lines of evidence suggest that PAF m ay playa role in 
epidermal pathophysio logy. First, PAF has been found in psoriatic 
scale [13] and in blister fluid from both traumatic [14) and buUous 
pemphigoid [15] blisters. Primary cultures of human keratinocytes 
have been shown to synthesize PAl" when sti mulated with the 
calcium iOllophore A23187 [16] . Second, intradermal injections of 
PAF resul t in wheal and flare reactions [17] . Third, PA F-R 
antagonists administered either systemically o r topicall y have anti-
inflammatory effects in murine model system s of contact dermatitis 
[1 8,19]. 
Although there is much ev idence suggesting a role for PAF in 
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epidermal fun ction, a keratinocyte PAF-R h as not yet bee n dem-
onstrated. In tills study, we uscd immuno fluorescen ce and radioli-
gand binding studies to ide ntify PAF-R immunoreacti v ity and 
sp ecific binding sites in human ke ratinocytes. C h arac te rization of 
P AF-induced changes in k e ratinocyte intra cellular free calcium 
u sing the calcium-sensitive fluorescent dye indo-l indicated that 
these binding sites w e re fun ctional receptors. T h e demonstration of 
a fun c tional k e ra tinocyte PAF-R su ggests that PAF may have direc t 
e ffects on keratinocyte function. 
MATEIUALS AND METHODS 
Reagents Labeled pAF (1-[' H]octadecyl-2-acetyl-glycerophosphocho-
line [GpC]. 161 C i/ mmol) was obtained fi'om Amcrsham Corp. (Arlington 
Heig hts, IL) . Unlabeled PAF (1-hexadecyl-2-(R)acetyl-G PC) and other 
phosph olipids used for chromatograph y were purchased fro m Biomol 
R esear ch Labs (Plymouth, pA). Lyso PAF (1-hexadecyl-2-(R)lyso-GPC). 
S-PAF (3-hexadccyl-2-(S)ace tyl-1-GpC), f.,tty acid-frec bovinc serum al-
bunlln (BSA). l-lEpES, phenanthroline. phcnylmcthylsulfonyl Ruoride , leu-
peptin. and aprotinin A were plll'chascd rrom Sigma C hcmica l Co. (St. 
Louis, MO) . C V-620 9 was a kind gift of Dr. Hajimc Toguchi (Takcda 
Chel11.ica l Industrics, Japan). Ro 19-3704 was kindly provided by Dr. Petcr 
Sorter (Hoffinan-La Roche, Inc., Nutlcy, NJ). Alprazolam was a genero us 
gift from the UpJohn Co. (Kalamazoo, MI). 
Cell Culture Primary cultures of human ncollatal kcratinocytes and 
fibroblasts werc isolatcd from fo reskins as described prev iously [20]. All 
tissue culturc media and supplcments were obtaincd from Gibco (Grand 
Island , NY) . Human neona ta l keratinocytes were grown in keratinocyte-
serun" free medium supplcmcntcd with antimicro bials (pcnicillin 10 ,000 
U/rrtL, streptomyc in 10 mg/mL, fun gizonc 25 J..Lg/ mL) and werc used aftcr 
the second passage (days 18-22). Human nconatal foreskin fibrobla sts were 
gro""n in M-1 99 mcdia witll antimicrobia ls and wcre used within the first 
month of cultlll'e. T hc epidermoid cell line A-431 was obtaincd from 
Am e rican Type C ulture Collcction (Rockville , MD) , and HaCaT cells [21] 
wer e a kind gift from Professor Norbert Fusenig (German Cancer Research 
Center, Heidelberg, Germany) . The keratinocytc cell lines were grown in 
Dulbecco's modified Eagle's medium supplemcnted with 5 mM HEPES , 
L-gi u tamine, and antimicrob ials. For use in the mctabo li sm. binding, and 
calci um studies . adherent cell s were harvestcd while 80% to 90')1" conRuent 
by treatmcnt with 3 mM cthylenediaminete traacctic acid in phosphatc-
bufFered sa linc (PBS) at 37°C for 30 min. with gcntl c sc raping. T he ccll s 
were w as hed at least twice with Hanks ' balanced sa lt solution (HBSS) 
wi thout phcno l rcd, which contained (in mM) : 138 NaC I, 5 KC I. 0.3 
KH 2 PO." 0.3 Na2 HPO., 0.5 MgCl,-6H 2 0, 0.4 MgSO.,-7H 20, 4 
NaHC03, 1.3 aC12, 5.6 glucose, and 25 HEPES at pH 7.4. 
Measuremcnt of PAF-R Irnmunofluorcsccncc ImmunoRuorescencc 
studies to characterize the keratinocyte PAF-R used a rabbit polyclollal 
antibody directcd aga inst a decapeptidc cxpressed on the extracellular 
portion ofthc human PAF-R. T his antibody (anti-hPAF-P'.' ''·-I7') has been 
sho""n to be specific for the PAF-R by both Ruoresccnce-activated cell 
sorter ana lysis and Western blotting [22]. ImmunoRuorescence studies used 
eithe r anti-hPAF-R' ''''- ' 73 or a control antibody 6'om rabbits immunizcd 
agains t thc carricr keyhole limpct hemocyanin (anti-KLH) alonc, purified as 
described [22], diluted 1 :100 with PBS. Keratinocytes were cultured in 
Vitrogen 100 (C elt";'x , Santa C lara, CA) prctreated Lab-tek Chamber slides 
(N unc, Naperville, IL) . Subconfiuent culturcs wcre wash cd twice with cold 
PBS a nd incubated with either anti-hPAF- R",·,- ' 73 or anti-KLH for 2 h at 
4°C. T he primary antibodies were then rcmovcd. and the slidcs were 
wash e d with co ld PBS. The cell s were tllCn incubated with a 1:1 00 dilution 
of affi nity-iso lated Ruorescein isothiocyanate (FITC)-Iabclcd goat F(ab ' )2 
an ti-rabbit IgG (Biosource Int .. Carrillo. CA) for 2 h at 4°C . thcn washed 
twice with co ld PBS and dried brieRy befo re acetone fixation. Skin 
speci.n1ens were taken from extra tissue fi'om yo ung adults undcrgoing 
cosn~eti c procedurcs. The tissucs wcrc embcddcd in OCT (Mi lcs Inc .. 
El.kha rt, IN) , frozen in liquid n.itrogen . and storcd at - 70°C until used. Thc 
skin was sectioned at 5 J..Lm on a cryostat. SectiollS wcrc placcd on 
gela tin-coated slidcs and incubated with anti_hPAF_R" ,"- ' 7J o r anti-KU-I 
antibody for 2 h at room temperature, rinsed with PBS, thcn incubated with 
me FITC-Iabeled secondary antibody for '1 h at room tcmpcrature. Covcr-
slips ""ere mounted and the slidcs werc examined on an O lym pus Ruores-
cen ce microscope. 
Measurement of ['HlPAF Mctabolism A-431 cc lls (2.5 X 10") wcre 
wash e d and resuspended to a final volume of 0.95 1111 of HBSS. To the 
above ce ll suspcnsion. wc added 50 J..L I of aqueo us solution containing 
['H]PAF complexcd to BSA (2.5 mg/ ml). bringing thc final concentration 
to 1 X 10- 0 M . The incubation mixturc was shaken gcntl y at either 37°C 
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or 4°C for '1 20 min. The rcaction was tcrminated by addition of3.75 ml of 
chloro form / mcthanol (1:2 v /v ) to thc ce ll suspcnsion, and the lipids wcre 
cxtracted using the technique of Bligh and Dycr [23]. T he recovercd 
pro ducts \vere those present in bo th the cell s and 111CdiuI11 , and the recovery 
of tritium label in the lipid fraction was greater than 85%. Solvents were 
removcd by a stream of nitrogen, and the lipids were resuspend cd in 
chlorofonn/ mcthanol (1: 2 v/v). The phospholipids and phosphol ipid stan-
dards werc scparated On sili ca gel G th in-Iaycr chromatograph y (TLC) 
platcs (A nal tech, Newark, DE) using an acid.ic so lvent sys tem containing 
chloroform/ methano l/glacia l acctic acid / watcr (65 :35:8: 1, v/v). Thc dis-
tribution of radiolabel was determined using an automatic TLC Iincar 
ana lyzer (Bcrtho ld. Germany). 
Measurement of ['HlPAF Binding SubconRuent cultures of A-431 
ce lls (150-200 X 10" ce ll s) were washed and resuspended to a final volumc 
of 20 ml with PBS containing the protcasc inhibitors phenanthro linc (I 
mM) , phcnylmethylsulfonyl Ruo ridc (100 J..LM). aprotin.in A (10 J..Lg / mL). 
and leupeptin (10 J..Lg/ mL). The ce llular suspension was sonicated on icc. 
thcn centrifuged at 100 X g to rcmovc whole cells. Thc supcrnatant was 
rcmovcd and centrifuged at 100 .000 X S for 60 min at 4°C. The rcsulting 
pellct was resuspended in binding bufFc r. which contained (in mM): 10 
NaC I, 5 MgC I2-6H20, 5 MgSO.,-7H2 0 . 10 CaCI2• 5. 6 glucose, and 10 
Tris-HCI at pH 7.0. Aliquots of crudc mcmbrane (50 J..Lg protein ; measurcd 
by protein assay [24]) wcre placed in 15 X 85-mm glass tubes prctrca tcd 
with Sigmacote (Sigma), with a fi nal volumc of 0.4 ml. Suspensions were 
thcn simultaneously exposed to 50 J..LI of aqucous solution con ta ining 
[' H]PA F complexed to BSA (10 mg/ml ), plus eithcr 50 J..Ll unlabe lcd PA F. 
lyso PAF, o r C V -6209 complcxed to BSA, or BSA alone. T he mixture of 
crudc membranes, [' H]PAF, and inhibitors was shaken gently at 4°C for thc 
appropdatc ti111CS . Each sanlpic \vas rUIl in tripli ca te. Suspensio ns \verc 
harves ted by suction through GF/C filters (Whatman) premoistcncd with 
10 mg/ ml BSA using a Hocffcr Filtration apparatus (Hocffer Scientifi c. San 
Francisco, CA). Thc tubcs were thcn was hcd threc times witll 5 ml of cold 
binding buffer. The filters were air dri ed and placcd in 10-ml scintillation 
vials, to which 7 ml of ScintiveL'sc (Fisher, Fairlawn, NJ) was added. The 
vials were coun tcd in a Beckman LS6800 scintillation CO untcr that was 
programmcd to measure each sam pIc 's quench and to determine dpm fi'om 
cpm using tritium standards. 
Intracellular Calcium Measuremcnts Adhercnt cclls werc harvcstcd 
while 80% to 90% conRuent by treatment with 3 mM ethylenediaminc-
tetraacetic acid in PBS at 37°C for 30 min. with gcntl c scraping. T he ce lls 
were washcd at Icast twice with HBSS witho ut phenol red . Cells (0.5-
'1.0 X 10"/ml) werc thcn loaded with thc Ca + + -sensitivc indicator, indo- I 
AM ('I J..LM; Calbiochem, San Dicgo, CA), in HBSS at 37"C for 45 min. 
After loading. thc cells were spun down , resuspcnded in HBSS . and 
maintaincd at room temperature. Beforc each mcasurement, an aliquot of 
the cell suspension (1.0-1.5 X 106 ) was pclleted rapidly by centrifugation 
and rcsuspended in 3 ml ofHBSS. PAF and PAF-R antagonists were addcd 
in 2.5- 5 J..LI cthanol. Endothelin-l was added in PBS buffer. Indo-I 
Ruorcscence was mOl~itored in a Hitachi F-4010 spectrophotometer. Mea-
surcments were performcd at 37°C witll constan t stirring. T he cxcitation 
and cmission wavclengths of the Ruorescent dye w cre 331 and 410 nm. 
respectivcly, and [Ca++]; was calculatcd as described [25]. 
RESULTS 
PAF-R Expression at the Cell Surface of Cultured Kerati-
nocytes and Skin Slices To charac tc l;ze the expression of 
PAF-R at the prote in level, we used a rabbit polyclon a l antibody 
against a decap c ptide (hPAF_R' 64- ' 7, ), corresponding to a segm ent 
in the second extracellular loop of the putative struc ture of the 
human PAF-R., in immunofluorescen ce studies as d escribe d in 
Materials alld I'dethods. The anti-hPAF-R 1(,.1- 173 antibody bound to 
the surface of c ultured hum an keratinocytes and to thc keratinoC)'te 
ce ll lines A-431 and HaC aT, as sh own in Fig lA-D. The granu lal' 
p a ttern of fluores cen ce oudin ing the cell s w as consiste nt with that 
of a membranc receptor. Indirect immunofluo rcscen ce with control 
antibody (anti-K.LH) did not produce' similar staining (Fig iF). 
Inc ubation of anti- hPAF-R' 64 - , 73 antibody with primary c ultures 
of human fibroblasts (Fig lE) or the m e lanoma cell tinc SK-30 
(data not shown) did not demonstra te diffcren ces in fluorescen ce 
above the background found with anti-KLH. In c ubation of slcin 
slices with anti-PAF-RI(>·' - ' 73 antibody resulted in selective bind-
ing to the epidermis (Fig 2) in a granular patte rn on keratinocyte 
m e mbranes . most intense on the supra basal cell s . 
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Figure 1. Indirect immunofluorescence labe ling of human keratinocytes. C ultured keratinocytes were incubated with either anti_hPAF_R' 64- ' 73 
o r anti-KLH, washed, and incubated w ith FITC-conjugated goat anti-rabbit IgG, as described in Mnlerin /s nm/ Melfl"ds. The anti_ hPAF_R' 64- ' 73 antibody 
gave granular staining o f the cell m embranes on (A) human neo natal foreslcin keratinocytes (600 X), (8) A-43 1 cell s (400 X). (C) HaCaT ce lls (600 X), and 
(D) H aCaT ce ll s (200 X), but did not stain (E) human neonatal foreslci n fibrob lasts (400 X). T he an ti-KLH control antibody fililed to stain primary cultures 
of human neonatal keratinocytes, A-431 cell s, HaCaT cell s, or primary cultures of human neonatal fo reskin fibroblasts. F. an example of the anti-KLH 
anti body sta ining in A-431 cell s (400 X). 
Metabolism ofPAF by A-431 Cells Because it was not known 
whether keratinocytes metabolize PAF, [3H]PAF was incubated 
w ith A-431 cell s and the products were examill ed by TLC, as 
described in Materials Il lld Methods. Figure 3 shows the distribution 
of label in PAF, lyso PAF, l - alkyl-2-acyl-GPC, and neutral lipids 
after incubation with A-43 1 ceUs for 2 h at 37°C and 4°C. A-431 
ceUs readily metabolized PAF at 37°C , with l-alkyl-2-acyl-GPC 
the major produ ct, indicating that these cells metabolize PAF by the 
deacetyla tion-reacylation pathway found in other tissues [26,27]. 
Tlus metabolism was temperature dependent, with milumal PAF 
degradation at 4°C. The products shown in Fig 3 were extracted 
from the complete incubation mixture and thus represent products 
derived from both cells and m edium. Incubation of CH]PAF under 
standard conditions at 37°C in the absence of cell s resul ted in 
negligible me tabolism of [3H]PAF (resul ts not shown). 
Binding ofPAF to A-431 Membranes Because ligand metab-
oli sm can result in spurious binding resul ts, PAF binding studies 
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were conducted at 4°C . The kinetics of PAF binding to A- 431 
membranes were examined. C rude membrane preparations of 
A-431 cells (approximately 50 JoLg protein) were incubated in 
triplicate with 1 nM of [3H]PAF, with or without 1 JoLM of 
unlabeled PAF, and the binding was q uantified as described in 
Materials alld Methods. As indicated in Fig 4, specific binding 
reached saturation by 120 min. T he affi ni ty and number of PAF 
binding sites in A-431 cells were determined by constructing 
saturation binding isotherms. As demonstra ted in Fig 5, PAF 
specific binding increased with the concentration of labeled ligand 
and reached saturatio n. The data were then subjected to Scatchard 
analysis [28] to quantitate the number of binding sites present and 
their apparent affinity. Scatchard analysis of four separate experi-
ments gave a linear plot (representative experiment shown in Fig 
5), indicatin g a single population of PAF binding sites. The 
equilibrium dissociation constant (KD ), representing the affin ity of 
the PAF binding site, was calculated to be 6.3 ~ 0.3 nM . The Bmax , 
representing the total number of specific binding sites present, was 
calcula ted to be 1.0 ~ 0.1 pmollmg protein . Assuming an equinlo-
lar ligand-receptor complex and 100 X 10(' ce ll s yielding 2.1 m g of 
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Figure 2. Indirect itnmullofluorescence l a -
beling of sections of normal human skin. 
Five-micron-thick cryostat sections were incubated 
with either anti_hPAF_R" ,4- 173 o r anti- KLH , 
washed , and incubated with FITC-conjugated goat 
anti-rabbit IgG as desc ribed in Materials alld IIIlct"-
ods. Granular staining of the keratinocyte ce ll m em-
branes was seen w;th the anti- hPA F-R 164 -1 73 an-
tibody (A) , but not with the anti- KLH antibody (B) 
(400 X). 
crude m embrane protein under o ur experimental conditions, the 
above B",," x corresponds to 120 ~ 12 binding sites per A- 431 cell . 
The specificity of PAF binding was examined by conducting 
competition binding studies with unlabeled PAF, the PAF-R 
antagonist CV-6209, and lysoPAF (Fig 6) . Both unlabeled PAF and 
CV- 6209 (50% inhibitory concentration = 4.9 and 10.5 nM , 
respectively) competed with eH]PAF for binding to A-431 mem-
branes, whereas lysoPAF was inactive. 
PAF-Induced Intracellular Calcium Mobilization To de-
termine whether the binding sites on human keratinocytes were 
functionally ac tive, we measured changes in rCa + +1 induced by 
PAF using the fluorescent probe indo-·1. PAF caused a transient 
increase in intracellular free calcium in a dose-dependen t m anner. 
As illustrated in Fig 7 , [Ca++ l began to increase 5 to 10 seconds 
after the addition of P AF and returned to baseline within several 
minu tes. Repeat stimulation with PAF resulted in little change in 
rCa ++ ]; , suggesting homologous desensitization (results not 
shown). Dose-response curves in Fig 8 charactet;ze the relation 
between maximal changes in rCa + +1 and PAF concentration for 
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F igure 3. Distribution of labe l in products after incubation of 
1- ['H]octadecyl- 2- acetyl-GPC with A - 431 cells. T he cell s were incu-
bated for 120 min at 4°C (das" ed lill e) and 37°C (solid lille) , and the lipids 
were extracted as described in Malerials alld Metll"ds . An aliquot of the 
labeled products was separated on TLC and radioassayed. T he peak 
numbers identifY the following lipids: 1-[3H]octndecyl- 2-lyso-GPC (peak J, 
RF = 0.26) , 1-[' H]octadecyl-2-acetyl-GPC (peak II, RF = 0.3 1), l -['H]octa-
decyl-2-acetyl-GPC (peak 111 , IUO = 0.51), unkJlOwn component (peak lV, 
RF = 0.77), and neutral lipid comignlting with 1- [3H]octadecyl-2-acctyl 
glycerol (peak V). 
primary cultures of human keratinocytes and A-431 cells. PAF 
treatment of indo- I-loaded HaCaT cells resulted in calcium re-
sponses similar to those in A-431 cells (data not shown) . T he 
change in [Ca ++]; was evident at a PAF concentration as low as 10 
pM. T he m edian effective concentration for the Cllrves generated 
were 780 pM and 1.5 nM for primary cultures of human keratino-
cytcs and A-431 cells, respectively. S-PAF, the biol ogically less 
active enantiomer of PAF, was a much less potent stimulus for 
A-43I calcium m obilization than was nati ve PAF. T he structurally 
dissimilar PAF-R antagonists CV -6209, Ro19-3704, and alprazo-
lam all inhibited PAF-induced calcium flu x in a dose-dependent 
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F igure 4 , Kinetics of ['H]PAF binding to A-431 cell membranes at 
4°C, C rude membrane prote in (50 p.g) was incubated w ith 1 nM [3H )PAF 
for the indicated time and harvested as desc ribed in Malerials ami Meillods. 
Specific binding (closetl circles) was the difl:c rence between PAF binding in 
the absence (oPell s1"ares) and presence (closed s1""res) of excess unlabeled 
PAF (1 p.M). Each point is the mean :!: SEM PAF bind ing of two separate 
experiments using triplicate samples. 
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Figure 5 . Saturation kinetics and Scatchard analysis of [JH]PAF 
binding to A-431 membranes. Saturation binding iso therms were con-
structed (illset) by equilibrium (120 min) binding of 0.05 to 10 nM [3H]PAF 
to A-431 membranes. The data were subjected to Scatchard anal ysis. T he 
da ta pictured are from a single experiment using triplicate samples and is 
represen tative of four separate experiments. T he binding affin ity (Ko) and 
maxim um binding (B",,,xl were ca lcu lated from the Scatchard plot and were 
found to be 6.3 :!: 0.3 nM and 1.0 :!: 0.1 pmol/mg protein, respectively 
(m ean :!: SEM £i'om fo ur separate experiments). 
maImer, as illustra ted in Fig 9. This inhibition of the PAF-induced 
increase in [Ca + +]; by these PAF-R antagon.ists was specific for 
PAF, because pretreatment of A-431 cells or primary cultures of 
human keratinocytes with 10 nM CV- 6209, 1 IJ.M Ro19-3704, or 
100 IJ.M alprazolam did not affect 10 nM endothelin-l -induced 
calcium mobilization (Fig 7) . The concentrations of PAF, S-PAF, 
or PAF-R antagonists did not affect cellular integrity as measured 
by trypan blue dye exclusion . PAF (100 nM) treatment of indo-l-
loaded primary cultures of fibroblasts, primary cultures of human 
m elanocytes, and the m elanoma cell line SK-30 did not affect the 
baseline fluorescence (data not shown) . 
DISCUSSION 
These studies demonstrate that human keratinocytes express func-
tional PAF-Rs. Indirect immllnoflu orescence studies using a poly-
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Figure 6. Compctition of[JH]PAF binding to A-431 mcmbranes b y 
PAF and CV- 6209 . A-43 1 membranes were incubated w ith 1 nM 
['H]PAF and difFerent conccntrations of unlabeled l - hcxadecyl-2-acetyl-
GPC (circles), CV-6209 (s1"ares), lyso PAF (tri""gles) , or J3SA alone fo r 120 
min and harvested as described in Mnterials alld Melhads. The data are 
expressed as the m ean :!: SEM percentage of specific binding observed at 
each concentration of analogue from three or four separate experiments. 
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Figure 7. PAF-induced intracellular Ca ++ mobilization in human 
neonatal foreskin keratinocytes. Indo- I-loaded keratinocytes were 
incuba ted in HBSS containing 1.4 mM CaCl2 and challenged with (A) 1 nM 
PAF or (B) 10 nM C V-6209 before PAP treatment. As shown (B), 
pretreatment of ce ll s with CV-6209 did not affect the calcium mobilization 
indu ced by 10 nM cndothclin-l. These arc typical resu lts fi·om at least four 
o r five separate cxpcri lll cnts. 
clo n a l anti-peptid e antibody (anti_hPAF_RI 64 - 173), w hich h as 
been shown to be specific for the PAF-R in m o nocytic, neutro-
philic, and B-Iymph o blastic cell lin es [22], showed binding of 
anti- hPAF-R 1 (,·1- 173 an tibody to primary cultures of human kera-
tinocytes and the keratinocyte cell lines A-431 and Ha CaT. Mic-
rotome sections of normal human skin also demonstrated a granu-
lar, cell ular membrane pattem of anti_hPAF I6'1- 173 antibody binding 
localized to the epidermis (Fig 2). Anti_hPAF1(,.1- 173 immunoreactiv-
ity was slightly more prominent in the squamous and granular layers, 
with l ess in the basal layer. Anti_hPAF_R 1(,.1- 173 staining spared the 
horny layer (stratum com eum), suggesting that cellular viability is 
necessary for PAF-R expression . 
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Figure 8. Concentration dependence of intracellular Ca++ mobi-
lization. Indo-I-loaded (A) human neonata l foreskin keratinocytes or (B) 
A-431 ce lls were treated with 100 I'M to 1 fLM PAF (circlrs) or 1 nM to 5 fLM 
S-PAF (squares). and the peak change in [Ca ++); was calculated. T he values 
arc mean :t SEM frol11 three to eight separate experiments. 
Because of the large number of cells n eeded and the advantages 
inherent in using a homogeneous source of cells instead of primary 
cultures (which can contain small amounts of oth er nonkeratino-
cyte skin cells), w e u sed the cell li n e A- 431 in both the m etabolism 
;lI1d binding experiments. A-431 cells m etabo lized PAF at 3 rc by 
transacylation , similar to that found in other cells such as n eutro-
phils [26], lymphocytes [27], and plate lets [29] . To avoid binding 
artifacts due to ligand m etabolism , we conducted binding assays on 
crude membran e preparations of A-431 cells at 4°C, a temperature 
at which th ese cells do n ot appreciably m etabolize PAF. [3H]PAF 
specific binding in creased over time and reach ed equilibrium by 
120 min. Scatchard analysis of saturation binding isotherms re-
vea led a sing le class of high-affinity binding sites, which had a KD 
of 6.3 ± 0.3 11M (Fig 5) . This Ko found for A- 43 1 cells is similar 
to reported va lues for hum an platele ts [30] and Raji lymphoblasts 
[31], and is somewhat highe r than repo rted va lues for human 
neutrophils [32]. The number of bindin g sites was estim ated to b e 
120 per cell. PAF and CV- 6209 , but n ot the biolog ically inactive 
PAF precursor lyso PAF, competed w ith CH]PAF for binding to 
A-431 m embranes . . 
The anti_PAF_R 1(,4 - 173 immun oreactivity and r3H]PAF binding 
sites fo und on human keratinocytes were shown to be functional 
PAF-Rs because PAF treatment resulted in intracellular calcium 
mobilization . The m edian effec tive concentration of the PAF-
indu ced calcium mobi lization was similar to the Ko derived from 
the binding studies . T h e pattern of PAF-induced increase in 
ke ratinocyte [Ca ++ ]; was similar to th at described in o the r cell 
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Figure 9. Concentration dependence of the inhibition of PAF-
induced intracellular calcium mobilization in A-431 cells by 
PAF-R antagonists CV-6209, Ro19-3704, and alprazolam. Indo-l-
loaded A-431 cells were pretreated with various doses ofCV-6209 (circles), 
Ro19-3704 (sqllal'es). or alprazolam (triallgles) for 1 min. followed by 500 
pM PAF. The peak change in [Ca++ J; was calculated. Each point is the 
mean :t SEM of the percentage of peak change of[Ca++]; induced by PAF 
alone from three to five separate experiments. 
types [31]. The structurally dissimilar PAF-R antagonists CV -6209. 
R019-3704, and alprazolam all inhibited this PAF-induced re-
sponse (Fig 9), yet had no effect on endothelin-1-induced intra-
cellular calcium mobilization (Fig 7) . Primary cultures of human 
fibroblasts or the melanoma cell line SK-30 did not display 
anti_hPAF_RI 64-173 immunoreactivity, and PAF treatment of these 
cells did not result in intracellular calcium mobilization (results not 
shown). 
In platelets, the PAF-R is functionally linked to inositol-specific 
phospholipase C, with resultant production of inositol-1,4,5 
trisphosphate and diacylglycerol [9]. The intracellular calcium 
mobilization that is seen with PAF-R activation is due at least in 
part to inositol-1,4,5 trisphosphate-stimulated release ofintracellu-
lar (nonmitochondrial) stores of calcium [33]. Our finding that 
PAF-R activation stimulates an increase in keratinocyte rCa + + 1. is 
consistent with a previous report that PAF treatment of cultured 
human keratinocytes (but not fibroblasts) resulted in phosphoino-
sitol hydrolysis [34]. The neutral lipid diacylglycerol formed by 
phosphoinositol hydrolysis is known to activate protein kinase C by 
facilitating translocation of this enzyme from the cytosol to the 
extracellular membrane [35] . 
We detected 1-alkyl neutral lipids when A-431 cells were 
incubated with PAF (Fig 3). The 1-alkyl-2-acetylglycerols, which 
are neutral lipid products ofPAF degradation by phospholipase C, 
also activate protein kinase C [3]. Alternatively, 1-alkyl-2-acyl-
glycerols, which can also be produced by PAF degradation 
(transacylation followed by phospholipase C degradation), can 
inhibit protein kinase C activation [36]. These l-alkyl neutral lipids 
are thought to exert their effects independent of the PAF-R and 
thus would not be blocked by PAF-R antagonists. Inasmuch as PAF 
acring through its receptor and PAF degradation products could 
theoretically have either similar or opposite biochemical effects, 
demonstration of a functional keratinocyte PAF-R (inhibited by 
PAF-R antagonists) is an important first step in the future evalua-
tion of PAF effects on this cell type . 
The role of the PAF-R in kerarinocyte function is not clear. 
However, the finding by Pignol et al [37] that PAF potentiates 
interleukin-1 production by lipopolysaccharide-stimulated guinea 
pig kerarinocytes suggests that activation of the keratinocyte 
PAF-R may augment inflammation. PAF-R antagonists have been 
shown to have antiinflammatory effects in animal models of cuta-
neous inflammation, including allergic and irritant contact derma-
titis in the mouse [17,18] and burn edema formation in the rabbit 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
[38] . The availability of PAF-R antagonists may allow further 
characterization of tills potent autacoid in kerarinocyte pathophys-
iology, information that could lead to better treatment strategies for 
inflammatory dermatoses. 
We ackllolVledge the tecl",ical assistallce oj Ms. Tall/ara Zekll/all alld The New Lab 
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